ArticleRespiratory research2021
Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes.
Article in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- Trial
- Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis.Nature communications · 2026Article
- Comparison of the effectiveness of pirfenidone and nintedanib in patients with advanced stage idiopathic pulmonary fibrosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases.BMC pulmonary medicine · 2024Article
- Blood urea nitrogen-to-albumin ratio as a new prognostic indicator of 1-year all-cause mortality in patients with IPF.Frontiers in medicine · 2024Article
- Comparison of Physical Activity Patterns among Three Major Chronic Respiratory Diseases.Journal of clinical medicine · 2023Article
- Lung function trajectories in patients with idiopathic pulmonary fibrosis.Respiratory research · 2023Observational
- Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2023Article
- The 6-min walk test as a primary end-point in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Review
- Idiopathic pulmonary fibrosis: Current and future treatment.The clinical respiratory journal · 2022Review
- Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
research questionThere is no widely accepted grading system for IPF disease severity, although physiologic impairment based on pulmonary function testing is frequently employed. We sought to describe clinical and functional characteristics as well as outcomes of patients with severe physiologic impairment. PATIENTS AND
methodsIPF patients with severe physiologic impairment defined by FVC ≤ 50% and/or DLco ≤ 30% predicted evaluated in the Inova Advanced Lung Disease Program between 2011 and 2019 were included. Demographic, physiologic, functional treatment and outcome data were collated.
resultsThere were 531 patients with IPF evaluated of whom 242 (46%) had severe physiologic impairment. Mean age was 72 ± 8 years; baseline FVC was 53 ± 17% and DL
conclusionIPF patients often present with severe physiologic impairment which may be poorly correlated with their functional status. Assessment of IPF disease severity should not be based on physiologic impairment alone, but should also encompass functional status as well as need for supplemental oxygen. Antifibrotic therapy in patients with severe physiologic impairment is associated with improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.